Australia's TGA issues safety advisory for the Zostavax vaccine

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2021年 / 1837卷 / 1期

关键词：

D O I：

10.1007/s40278-021-88600-6

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：1 / 1

相关论文

共 50 条

[21] Australia's TGA outlines PV obligations of medicine sponsors
Reactions Weekly, 2021, 1841 (1) : 1 - 1
[22] Vaccine safety monitoring reforms needed in Australia
Reactions Weekly, 2011, 1354 (1) : 4 - 4
[23] The BCG vaccine: information and recommendations for use in Australia National Tuberculosis Advisory Committee
不详
COMMUNICABLE DISEASES INTELLIGENCE, 2006, 30 (01) : 109 - 115
[24] METHODOLOGICAL ISSUES IN THE EVALUATION AND MONITORING OF VACCINE SAFETY
FINE, PEM
COMBINED VACCINES AND SIMULTANEOUS ADMINISTRATION: CURRENT ISSUES AND PERSPECTIVES, 1995, 754 : 300 - 308
[25] Australia's TGA takes tough stance on COX-2s
Reactions Weekly, 2005, 1039 (1) : 3 - 3
[26] Australia's TGA prevented from implementing meloxicam labelling changes
Reactions Weekly, 2005, 1048 (1) : 2 - 2
[27] Australia's TGA offers tips on how to identify counterfeit medicines
Reactions Weekly, 2020, 1796 (1) : 2 - 2
[28] Measles, mumps and rubella vaccine - Current safety issues
West, R
Roberts, PM
BIODRUGS, 1999, 12 (06) : 423 - 429
[29] mRNA: Vaccine or Gene Therapy? The Safety Regulatory Issues
Banoun, Helene
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (13)
[30] Post-licensure safety surveillance of zoster vaccine live (Zostavax®) in the United States, Vaccine Adverse Event Reporting System (VAERS), 2006-2015
Miller, Elaine R.
Lewis, Paige
Shimabukuro, Tom T.
Su, John
Moro, Pedro
Woo, Emily Jane
Jankosky, Christopher
Cano, Maria
HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2018, 14 (08) : 1963 - 1969

← 1 2 3 4 5 →